SEC Form 4 · accession 0000911916-15-000316
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas P. Mathers
Officer — Chief Executive Officer · Director
Period of report
Aug 25, 2015
Accepted (ET)
Aug 25, 2015 · 3:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 25, 2015 | P | 7,500 | $7.1033 | A | 7,500 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the purchase of 7,500 shares in multiple transactions, ranging in price from $6.835 to $7.20 per share, resulting in a weighted average purchase price of $7.1033. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price within the range.